Tarun Kewalramani to Lymphoma, Non-Hodgkin
This is a "connection" page, showing publications Tarun Kewalramani has written about Lymphoma, Non-Hodgkin.
Connection Strength
0.692
-
Kewalramani T, Nimer SD, Zelenetz AD, Malhotra S, Qin J, Yahalom J, Moskowitz CH. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant. 2003 Oct; 32(7):673-9.
Score: 0.211
-
Kewalramani T, Moskowitz CH. Upfront transplantation for poor-risk aggressive non-Hodgkin lymphoma and Hodgkin's disease: who benefits? Curr Oncol Rep. 2001 May; 3(3):271-8.
Score: 0.178
-
Kewalramani T, Zelenetz AD, Hedrick EE, Donnelly GB, Hunte S, Priovolos AC, Qin J, Lyons NC, Yahalom J, Nimer SD, Moskowitz CH. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood. 2000 Oct 01; 96(7):2399-404.
Score: 0.171
-
Perales MA, Jenq R, Goldberg JD, Wilton AS, Lee SS, Castro-Malaspina HR, Hsu K, Papadopoulos EB, van den Brink MR, Boulad F, Kernan NA, Small TN, Wolden S, Collins NH, Chiu M, Heller G, O'Reilly RJ, Kewalramani T, Young JW, Jakubowski AA. Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT. Bone Marrow Transplant. 2010 Sep; 45(9):1408-16.
Score: 0.081
-
Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2003; 14 Suppl 1:i5-10.
Score: 0.050